KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2016 - 2025)

Jazz Pharmaceuticals has reported EBITDA Margin over the past 16 years, most recently at 21.25% for Q4 2025.

  • Quarterly results put EBITDA Margin at 21.25% for Q4 2025, up 372.0% from a year ago — trailing twelve months through Dec 2025 was 9.05% (down 2368.0% YoY), and the annual figure for FY2025 was 10.08%, down 2769.0%.
  • EBITDA Margin for Q4 2025 was 21.25% at Jazz Pharmaceuticals, up from 5.11% in the prior quarter.
  • Over the last five years, EBITDA Margin for JAZZ hit a ceiling of 26.68% in Q1 2021 and a floor of 65.64% in Q2 2025.
  • Median EBITDA Margin over the past 5 years was 10.76% (2022), compared with a mean of 5.19%.
  • Biggest five-year swings in EBITDA Margin: soared 6215bps in 2021 and later plummeted -8512bps in 2025.
  • Jazz Pharmaceuticals' EBITDA Margin stood at 5.51% in 2021, then plummeted by -592bps to 27.09% in 2022, then soared by 145bps to 12.11% in 2023, then soared by 45bps to 17.53% in 2024, then rose by 21bps to 21.25% in 2025.
  • The last three reported values for EBITDA Margin were 21.25% (Q4 2025), 5.11% (Q3 2025), and 65.64% (Q2 2025) per Business Quant data.